Dova Pharmaceuticals (DOVA) Downgraded to “Sell” at BidaskClub

BidaskClub cut shares of Dova Pharmaceuticals (NASDAQ:DOVA) from a hold rating to a sell rating in a report published on Thursday morning.

Separately, Evercore ISI began coverage on shares of Dova Pharmaceuticals in a research report on Friday, March 23rd. They issued a line rating and a $29.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $32.00.

How to Become a New Pot Stock Millionaire

Dova Pharmaceuticals stock opened at $27.12 on Thursday. The company has a market capitalization of $763.48 and a PE ratio of -19.37. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $37.00.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Thursday, February 15th. The company reported ($0.36) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.36). During the same quarter last year, the firm posted ($0.44) earnings per share. sell-side analysts expect that Dova Pharmaceuticals will post -1.45 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its position in shares of Dova Pharmaceuticals by 702.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock worth $137,000 after purchasing an additional 4,163 shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of Dova Pharmaceuticals in the third quarter worth $202,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Dova Pharmaceuticals in the third quarter worth $241,000. Virtus Fund Advisers LLC bought a new stake in shares of Dova Pharmaceuticals in the fourth quarter worth $318,000. Finally, Deutsche Bank AG lifted its position in shares of Dova Pharmaceuticals by 139.2% in the fourth quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock worth $337,000 after purchasing an additional 6,836 shares in the last quarter. 26.05% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Dova Pharmaceuticals (DOVA) Downgraded to “Sell” at BidaskClub” was originally reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.wkrb13.com/2018/04/02/dova-pharmaceuticals-dova-downgraded-to-sell-at-bidaskclub.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply